Results 251 to 260 of about 3,257,292 (311)

Production of reactive fluorine-18

International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1986
Production conditions are reviewed from the perspective of maximizing activity--both total and specific--of 18F as electrophilic or nucleophilic precursors, with minimal levels of interfering species. Careful target design can avoid many pitfalls, and telemetry of a few key variables can guide the way to reproducible yields, consistent with prediction.
R J, Nickles, S J, Gatley, J R, Votaw, M L, Kornguth   +3 more
openaire   +2 more sources

The Preparation of Fluorine-18 Labelled Radiopharmaceuticals

The International Journal of Applied Radiation and Isotopes, 1977
Abstract Progress in the preparation of fluorine-18 labelled radiopharmaceuticals is reviewed. The pharmacology and design of 18F-labelled organic compounds of biomedical interest, production of the radionuclide and methods of labelling which have been used to date are discussed. Emphasis has been placed on the practical chemical problems encountered,
A K, Horsch, K, Hudson, R W, Goulding, A J, Day   +3 more
openaire   +2 more sources

Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT

PET Clinics, 2008
PET with the glucose analog [18F]-FDG is increasingly used to monitor tumor response in patients undergoing chemotherapy and chemoradiotherapy. The clinical value of FDG PET for differentiation of residual tumor and therapy-induced fibrosis has been documented for gastrointestinal cancer.
Hinrich A, Wieder, Ken, Herrmann
openaire   +2 more sources

Metabolism of Fluorine 18 in Domestic Animals

American Journal of Physiology-Legacy Content, 1955
Amounts of F/sup 18/ sufficient to permit studies up to 10 hours duration in domestic animals with non-toxic levels of total fluorine have become available from cyclotron production. The initial rate of disappearance of intravenously injected F/sup 18/ from the blood was found to be 41 and 32% of the dose/min.
J D, PERKINSON, I B, WHITNEY, R A, MONROE, W E, LOTZ, C L, COMAR   +4 more
openaire   +2 more sources

Preparation of carrier-free fluorine-18

The International Journal of Applied Radiation and Isotopes, 1977
Abstract A method for the preparation of carrier-free fluorine-18 using a column of hydrous stannic oxide is described. The adsorption and desorption characteristics of the fluoride ion on the column has been investigated using F-18 as a tracer. The present study has confirmed that the fluoride ion is practically completely adsorbed on the column in ...
T H, Hsieh, K W, Fan, J T, Chuang, M H, Yang   +3 more
openaire   +2 more sources

A cyclotron method for the production of fluorine-18

The International Journal of Applied Radiation and Isotopes, 1966
Abstract Fluorine-18 is produced, with yields of up to 40 mc/hr, by the bombardment of water contained in a suitable target held in the external α-particle beam of a 30 MeV cyclotron: a method is described which is in routine use to produce samples for medical research purposes.
J C, Clark, D J, Silvester
openaire   +2 more sources

The half-life of fluorine-18

Journal of Inorganic and Nuclear Chemistry, 1964
Radiochemically pure 18F has been prepared by three different methods and its decay has been followed with β proportional counters and γ-ray counters in an effort to measure the half-life accurately. Analysis by a computer program that used the method of least squares gave a weighted mean half-life of 18F and a weighted standard deviation of the mean ...
J.D. Mahony, S.S. Markowitz
openaire   +1 more source

Fluorine-18 Labeling of Peptides and Proteins

2006
The pool of promising peptides worthy of investigation and evaluation for clinical use is continuously filled from different sources. Driven by the promising results obtained with peptides addressing somatostatin-2 receptor positive (sst2+) neuroendocrine tumours, other peptides targeting further receptor systems are being studied and evaluated ...
H J, Wester, M, Schottelius
openaire   +2 more sources

PET imaging of musculoskeletal tumours with fluorine-18 α-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET

European Journal of Nuclear Medicine, 2000
Fluorine-18 labelled alpha-methyltyrosine (FMT) was developed for positron emission tomography (PET) imaging, and its potential for clinical application in patients with brain tumours has been demonstrated. This is the first trial to compare FMT with 18F-fluoro-2-deoxy-D-glucose (FDG) for the evaluation of musculoskeletal tumours. Seventy-five patients
H, Watanabe, T, Inoue, T, Shinozaki, T, Yanagawa, A R, Ahmed, K, Tomiyoshi, N, Oriuchi, M, Tokunaga, J, Aoki, K, Endo, K, Takagishi   +10 more
openaire   +2 more sources

Fluorine-18 Fluorodeoxyglucose Uptake in the Retractile Testis

Clinical Nuclear Medicine, 1999
A 51-year-old man with a palpable mass in his right inguinal region had fluorine-18 fluorodeoxyglucose (F-18 FDG) whole-body positron emission tomography (PET) in our cancer screening program. FDG accumulated in the mass, suggesting a metabolically active lesion that was likely malignant.
H, Fujii, S, Yasuda, M, Ide, W, Takahashi, A, Shohtsu, A, Kubo   +5 more
openaire   +2 more sources